Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome?

Medical Hypotheses

Volumn 65, Issue 1, 2005, Pages 97-102

  Crentsil, Victor ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BUDESONIDE; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HAPTEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SALOZINAL; STEROID; SUBSTANCE P; UNCLASSIFIED DRUG;

ASTHMA; BIOAVAILABILITY; CELIAC DISEASE; DIARRHEA; DRUG EFFICACY; EXPERIMENTAL INFECTION; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INTESTINE MUSCLE; IRRITABLE COLON; LYMPHOCYTE ACTIVATION; MUSCLE CONTRACTILITY; MUSCLE DISEASE; NONHUMAN; PARASITE; PARASITOSIS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REVIEW;

EID: 18944362443     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.07.042     Document Type: Article

References (49)

1. Y. Ringel, A.D. Sperber, and D.A. Drossman Irritable bowel syndrome Annu Rev Med 52 2001 319 338
2. W.G. Thompson, G.F. Longstreth, D.A. Drossman, K.W. Heaton, E.J. Irvine, and S. Muller-Lissner Functional bowel disorders and functional abdominal pain Gut 45 Suppl. 2 1999 II43 II47
3. D.A. Drossman, W.E. Whitehead, and B.B. Toner What determines severity among patients with painful functional bowel disorders Am J Gastroenterol 95 2000 974 980
4. J.D. Wood, D.H. Alpers, and P.L. Andrews Fundamentals of gastroenterology Gut 45 1999 1 44
5. N.J. Talley, A.R. Zinmeister, C. Van Dyke, and L.J. Melton 3rd Epidemiology of colonic symptoms and the irritable bowel syndrome Gastroenterology 101 1991 927 934
6. R.S. Sandler, D. Drossman, H.P. Nathan, and D.C. McKee Symptom complaints and health care seeking behavior in subjects with bowel dysfunction Gastroenterology 87 1984 314 318
7. W.E. Whitehead, L. Bosmajian, A.B. Zonderman, P.T. Costa Jr., and M.M. Schuster Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples Gastroenterology 95 1988 709 714
8. K.A. Gwee, J.C. Graham, and M.W. Mckendrick Psychometric scores and persistence of irritable bowel after infectious diarrhea Lancet 347 1996 150 153
9. M.W. McKendrick, and N.W. Read Irritable bowel syndrome-post salmonella infection J Infect 29 1994 1 3
10. K.R. Neal, J. Hebden, and R. Spiller Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients BMJ 314 1997 779 782
11. D. Munzer, and C. Eyad Spastic colitis and irritable bowel syndrome: which expression is prevalent? (a review of 120 cases) Trop Gastroenterol 13 1992 27 35
12. L.A.G. Rodriguez, and A. Ruigomez Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study BMJ 318 1999 565 566
13. B. Isgar, M. Harman, M.D. Kaye, and P.J. Whorwell Symptoms of irritable bowel syndrome in ulcerative colitis in remission Gut 24 1983 190 192
14. R.C. Spiller, D. Jenkins, and J.P. Thornley Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute campylobacter enteritis and in post-dysenteric irritable bowel syndrome Gut 47 2000 804 811
15. A. Smout, F. Azpiroz, and G. Coreman Potential pitfalls in the differential diagnosis of irritable bowel syndrome Digestion 61 2000 247 256
16. G. Barbara, R. DeGiorgio, V. Stanghellini, C. Cremon, and R. Corinaldesi A role for inflammation in irritable bowel syndrome? Gut 51 2002 141 144
17. J.L. Salzmann, F. Peltier-Koch, F. Block, J.P. Petite, and J.P. Camilleri Morphometric study of colon biopsies: a new method of estimating inflammatory disease Lab Invest 60 1989 847 851
18. M. O'Sullivan, N. Clayton, and N.P. Breslin Increased mast cells in the irritable bowel syndrome Neurogastroenterol Mot 12 2000 449 457
19. R. Kuhn, J. Lohler, and D. Rennick Interleukin-10 deficient mice develop chronic enterocolitis Cell 75 1993 263 274
20. D.M. Turner, D.M. Williams, and D. Sankaran An investigation of polymorphism in the interleukin-10 gene promoter Eur J Immunogenet 26 1997 1 3
21. W.M. Gonsalkorale, C. Perrey, V. Pravica, P.J. Whorwell, and I.V. Hutchinson Interleukin-10 genotype in irritable bowel syndrome: evidence for an inflammatory component Gut 52 2003 91 93
22. R. DeGiorgio, G. Barbara, and P. Blennerhassett Intestinal inflammation and activation of sensory nerve pathways: a functional and morphological study in nematode infected rat Gut 49 2001 822 827
23. M. Delvaux Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome Gut 51 Suppl. 1 2002 i67 i71
24. G. Barbara, B.A. Vallance, and S.M. Collins Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice Gastroenterology 113 1997 1224 1232
25. G. Barbara, R. DeGiorgio, Y. Deng, B. Vallance, P. Blennerhassett, and S.M. Collins Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice Gastroenterology 120 2001 1729 1736
26. C. Ma, and S.M. Collins Disparity between mucosal inflammatory changes and muscle contractility in hapten-induced colitis in mice post colitis Gastroenterology 118 2000 5456
27. K.A. Gwee, S.M. Collins, and N.W. Read Increased rectal mucosal expression of Interleukin 1β in recently acquired post-infectious irritable bowel syndrome Gut 52 2003 523 526
28. B.A. Vallance, F. Galleazzi, S.M. Collins, and D.P. Snider CD 4 T cells and major histocompatibility complex II expression influence worm expulsion and increase intestinal muscle contraction during Trichinella spiralis infection Infect Immun 67 1999 6090 6097
29. F. Galeazzi, E.M. Haapala, N. van Rooijen, B.A. Vallance, and S.M. Collins Inflammation- induced impairment of enteric nerve function in nematode-infected mice is macrophage dependent Am J Physiol Gastrointest Liver Physiol 278 2000 G259 G265
30. R.B. Hiatt, and L. Katz Mast cells in inflammatory conditions of the gastrointestinal tract Am J Gastroenterol 37 1962 541 545
31. H. Tornblom, G. Lindberg, and B. Veress Histopathological findings in the jejunum of patients with severe irritable bowel syndrome Gastroenterology 118 2000 A140
32. A. Weston, W. Biddle, P.S. Bhatia, and P.B. Miner Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome Dig Dis Sci 38 1993 1590 1595
33. G. Barbara, and V. Stanghellini Neuro-immune relationships in the colonic mucosa of irritable bowel syndrome patients Neurogastroenterol Motil 12 2000 A272
34. K.A. Gwee Evidence of an inflammatory pathogenesis in post-infective irritable bowel syndrome Gastroenterology 114 1998 G3127
35. S.M. Collins, K. McHugh, and K. Jacobson Previous inflammation alters the response of the rat colon to stress Gastroenterology 111 1996 1509 1515
36. F. Cervero, and W. Janig Visceral nociceptors: a new world order Trend Neurosci 15 1992 374 378
37. E.A. Mayer, and G.F. Gebhart Basic and clinical aspects of visceral hyperalgesia Gastroenterology 107 1994 271 293
38. C. Huerta, L.A. Garcia Rodriguez, M.A. Wallander, and S. Johansson Risk of irritable bowel syndrome among asthma patients Pharmacoepidemiol Drug Saf 11 2002 31 35
39. C. O'Leary, P. Wieneke, and S. Buckley Celiac disease and irritable bowel-type symptoms Am J Gastroenterol 97 2002 1463 1467
40. H.C. Mitchison, H. al Mardini, S. Gillespie, M. Laker, A. Zaitoun, and C.O. Record A pilot study of fluticasone propionate in untreated celiac disease Gut 32 1991 260 265
41. H.R. Gillett, I.D. Arnott, and M. McIntyre Successful infliximab treatment for steroid- refractory Celiac disease: a case report Gastroenterology 122 2002 800 805
42. K.D. Fine, and E.L. Lee Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis Gastroenterology 114 1998 29 36
43. J. Miquel Plaza, S.A. Lopez, and D. del Pozo Evolution and treatment response in microscopic colitis Gastroenterol Hepatol 24 2001 433 439
44. A. Tromm, T. Griga, H.W. Mollmann, B. May, K.-M. Muller, and A. Fisseler-Eckhoff Budesonide for the treatment of collagenous colitis: first result of a pilot trial Am J Gastroenterol 7 1999 1871 1875
45. G.R. Locke, A.R. Zinsmeister, N.J. Talley, S.L. Fett, and L.J. Melton Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities The American Journal of Gastroenterology 1 2000 157 165
46. V.N. Preobrazhenskii Salozinal in the treatment of the irritable bowel syndrome in young persons Ter Arkh 71 1999 37 39
47. L. Bueno, and J. Fioramonti Effects of inflammatory mediators on gut sensitivity Can J Gastroenterol 13 Suppl. A 1999 42A 46A
48. S. Dunlop, D. Jenkins, and J. Naesdal Randomised double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome (PI-IBS) Gastroenterology 122 Suppl. 2002 A60
49. A. Miller-Larsson, B. Gustafsson, C.G. Persson, and R. Brattsand Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat Aliment Pharmacol Ther 15 2001 2019 2025